Patents by Inventor Aaron S. Hammons

Aaron S. Hammons has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligomer-beta blocker conjugates
    Patent number: 10881738
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: January 5, 2021
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Franco J. Duarte, Aaron S. Hammons
  • OLIGOMER-BETA BLOCKER CONJUGATES
    Publication number: 20190175743
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
    Type: Application
    Filed: February 15, 2019
    Publication date: June 13, 2019
    Inventors: Jennifer Riggs-Sauthier, Franco J. Duarte, Aaron S. Hammons
  • Oligomer-beta blocker conjugates
    Patent number: 10251959
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: April 9, 2019
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Franco J. Duarte, Aaron S. Hammons
  • OLIGOMER-BETA BLOCKER CONJUGATES
    Publication number: 20170360948
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
    Type: Application
    Filed: August 29, 2017
    Publication date: December 21, 2017
    Inventors: Jennifer Riggs-Sauthier, Franco J. Duarte, Aaron S. Hammons
  • Oligomer-nucleoside phosphate conjugates
    Patent number: 9365604
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number administration routes, exhibits advantages over previously administered compounds.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: June 14, 2016
    Assignee: Nektar Therapeutics
    Inventors: Zhongxu Ren, Jennifer Riggs-Sauthier, Timothy A. Riley, Laurie A. VanderVeen, Aaron S. Hammons
  • OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES
    Publication number: 20140371168
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number administration routes, exhibits advantages over previously administered compounds.
    Type: Application
    Filed: April 23, 2014
    Publication date: December 18, 2014
    Applicant: NEKTAR THERAPEUTICS
    Inventors: Zhongxu Ren, Jennifer Riggs-Sauthier, Timothy A. Riley, Laurie A. VanderVeen, Aaron S. Hammons
  • Oligomer-nucleoside phosphate conjugates
    Patent number: 8741858
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: June 3, 2014
    Inventors: Zhongxu Ren, Jennifer Riggs-Sauthier, Timothy A. Riley, Laurie A. VanderVeen, Aaron S. Hammons
  • Oligomer-Nucleoside Phosphate Conjugates
    Publication number: 20100286084
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.
    Type: Application
    Filed: September 18, 2008
    Publication date: November 11, 2010
    Applicant: Nektar Therapeutics
    Inventors: Zhongxu Ren, Jennifer Riggs-Sauthier, Timothy A. Riley, Laurie A. Vander Veen, Aaron S. Hammons
  • Oligomer-Beta Blocker Conjugates
    Publication number: 20100227865
    Abstract: The invention provides Beta-blocker drugs that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the Beta-blocker drug not attached to the water soluble oligomer.
    Type: Application
    Filed: March 12, 2008
    Publication date: September 9, 2010
    Inventors: Jennifer Riggs-Sauthier, Franco J. Duarte, Aaron S. Hammons